BMYBristol-Myers SquibbSigning up patients
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-Small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2/3
- Patients
- 500 (planned)
- Started
- Nov 5, 2025
- Main results expected
- Dec 15, 2028
- Fully finished
- Nov 15, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recommended Phase 3 Dose (RP3D) of BMS-986507
Measured over: Approximately 3 months after the first dose
Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07100080 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC